Ascletis Pharma (ASCLF) Stock Price, News & Analysis

Company Overview

Ascletis Pharma Inc. is a China-based biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines. The company has concentrated on therapies for viral diseases, oncology and metabolic disorders, with operations and commercial activities primarily serving the Chinese market.

Ascletis’ commercial portfolio has included Ganovo (danoprevir), an oral hepatitis C treatment and a direct-acting antiviral designed to inhibit the HCV NS3/4A protease. Ganovo received approval in China in 2018 and was developed as part of the company’s efforts to expand access to domestically developed treatments for chronic hepatitis C.

The company also maintains a research and development pipeline covering areas such as cancer immunotherapy, nonalcoholic steatohepatitis and other metabolic or infectious diseases. Its development programs have included antibody therapies, small-molecule candidates and treatments intended for oral administration. Ascletis was founded by Dr. Jason Yang, who has served as chairman and chief executive officer.

Key Stats

• Today's Range: $0.75 to $0.75
• 50-Day Range: $0.75 to $1.34
• 52-Week Range: $0.75 to $2.50
• Volume: 5,000 shs
• Average Volume: 2,719 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:ASCLF
• CIK: N/A
• Web: www.ascletis.com
• Phone: 86-571-8538-9730
• Fax: N/A
• Employees: 202
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A